Loading…
For low-intake subjects: defensible. The internet enthusiasm runs ahead of the specific-form evidence.
Total magnesium status matters most; specific-salt differences are smaller than claimed.
Our read is Limited Research. The mechanistic story is plausible and the early signals are interesting, but the human outcome data is thin: a limited evidence base (42/100) and only a divided field (50% consensus). At $10/month, taking magnesium glycinate daily is a bet on preliminary science rather than a settled recommendation.
Pulled the public claims about taking magnesium glycinate daily from proponents on file (a tracked voice) and weighed them against the more cautious voices in the field, then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Downside risk on taking magnesium glycinate daily is low at sensible doses, but low risk is not no risk: individual response varies, and a low-risk intervention is still only worth it if the benefit is real.
A well-designed human outcome trial — the kind that currently does not exist — demonstrating benefit at the doses people actually use.
The intervention improves the primary outcome at standard doses in healthy adults.
Mechanistic and trial evidence converge on a real, replicable effect.
Mechanistic and trial evidence converge on a real, replicable effect.
The intervention improves the primary outcome at standard doses in healthy adults.
Most of the support comes from short or small studies.
The headline effect shrinks once you account for trial quality.
Animal-model results don't translate to the human protocol being recommended.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.